U.S. pharmaceutical companies have experienced a mixed reaction to President Trump’s recent executive order aimed at reducing prescription drug prices through a “Most Favored Nation” (MFN) pricing policy.
Market Response:
Initially, pharmaceutical stocks dipped following the announcement, reflecting investor concerns over potential revenue impacts. However, the market quickly rebounded as the details of the executive order became clearer. Major pharmaceutical companies such as Pfizer and Eli Lilly saw their shares rise by just over 2%, while Merck & Co Inc experienced a sharp increase of nearly 5% . The broader biotech index also rose more than 4% .
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $588.2M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.0¢ | 30.0¢ | $544.0K | 1.780M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 1049306 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 309606 | 14 |
View Market Depth
| Last trade - 10.38am 24/06/2025 (20 minute delay) ? |
| BOT (ASX) Chart |